Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1
- PMID: 22391561
- DOI: 10.1038/onc.2012.49
Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1
Abstract
The endothelium plays a pivotal role in the progression of solid tumors and is considered a highly relevant target for therapy. However, it emerges that current clinical angiogenesis inhibitors that act through inhibition of tumor-derived growth factors are prone to inducing drug resistance. Therefore, markers of tumor endothelial cells (ECs) themselves provide attractive novel therapeutic targets. In a screen for markers of tumor angiogenesis, we recently identified high-mobility group box 1 (HMGB1), known to act as proinflammatory cytokine and chromatin-binding molecule. Here we report on the role of HMGB1 in angiogenesis by showing that its overexpression is associated with an increased angiogenic potential of ECs. HMGB1 stimulates the expression of players in vascular endothelial growth factor and platelet-derived growth factor signaling, both in vitro and in vivo. Importantly, we show that HMGB1 triggers and helps to sustain this proangiogenic gene expression program in ECs, additionally characterized by increased activity of matrix metalloproteinases, integrins and nuclear factor-κB. Moreover, we found that HMGB1 is involved in several autocrine and/or paracrine feedback mechanisms resulting in positive enforcement of HMGB1 expression, and that of its receptors, RAGE (receptor for advanced glycation end products) and Toll-like receptor 4 (TLR4). Interference in HMGB1 expression and/or function using knockdown approaches and antibody-mediated targeting to break this vicious circle resulted in inhibited migration and sprouting of ECs. Using different in vivo models, therapeutic efficacy of HMGB1 targeting was confirmed. First, we demonstrated induction of HMGB1 expression in the chicken embryo chorioallantoic membrane (CAM) neovasculature following both photodynamic therapy and tumor challenge. We subsequently showed that anti-HMGB1 antibodies inhibited vessel density in both models, accompanied by a reduced vascular expression of angiogenic growth factor receptors. Collectively, these data identify HMGB1 as an important modulator of tumor angiogenesis and suggest the feasibility of targeting HMGB1 for multi-level cancer treatment.
Similar articles
-
Knockdown of RAGE expression inhibits colorectal cancer cell invasion and suppresses angiogenesis in vitro and in vivo.Cancer Lett. 2011 Dec 26;313(1):91-8. doi: 10.1016/j.canlet.2011.08.028. Epub 2011 Sep 6. Cancer Lett. 2011. PMID: 21945853
-
Inhibition of tumor angiogenesis by HMGB1 A box peptide.Med Hypotheses. 2008;70(2):343-5. doi: 10.1016/j.mehy.2007.05.024. Epub 2007 Jul 13. Med Hypotheses. 2008. PMID: 17630223
-
Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1).Angiogenesis. 2008;11(1):91-9. doi: 10.1007/s10456-008-9093-5. Epub 2008 Feb 9. Angiogenesis. 2008. PMID: 18264787 Review.
-
Redox status of high-mobility group box 1 performs a dual role in angiogenesis of colorectal carcinoma.J Cell Mol Med. 2015 Sep;19(9):2128-35. doi: 10.1111/jcmm.12577. Epub 2015 Jun 23. J Cell Mol Med. 2015. PMID: 26099505 Free PMC article.
-
High-mobility group box-1 and its role in angiogenesis.J Leukoc Biol. 2014 Apr;95(4):563-74. doi: 10.1189/jlb.0713412. Epub 2014 Jan 22. J Leukoc Biol. 2014. PMID: 24453275 Review.
Cited by
-
Construction of biological networks from unstructured information based on a semi-automated curation workflow.Database (Oxford). 2015 Jun 17;2015:bav057. doi: 10.1093/database/bav057. Database (Oxford). 2015. PMID: 26200752 Free PMC article.
-
Association of HMGB1 Gene Polymorphisms with Risk of Colorectal Cancer in a Chinese Population.Med Sci Monit. 2016 Sep 26;22:3419-3425. doi: 10.12659/msm.896693. Med Sci Monit. 2016. PMID: 27665685 Free PMC article.
-
The implication and potential applications of high-mobility group box 1 protein in breast cancer.Ann Transl Med. 2016 Jun;4(11):217. doi: 10.21037/atm.2016.05.36. Ann Transl Med. 2016. PMID: 27386491 Free PMC article. Review.
-
Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization.J Cell Mol Med. 2014 Mar;18(3):480-91. doi: 10.1111/jcmm.12199. Epub 2014 Jan 22. J Cell Mol Med. 2014. PMID: 24450440 Free PMC article.
-
HMGB1/RAGE axis in tumor development: unraveling its significance.Front Oncol. 2024 Mar 1;14:1336191. doi: 10.3389/fonc.2024.1336191. eCollection 2024. Front Oncol. 2024. PMID: 38529373 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical